Original Article

Is Chronic Kidney Disease Comparable to Diabetes as a Coronary Artery Disease Risk Factor?

Authors: Arash Rashidi, MD, Arash Ghanbarian, MD, Fereidoun Azizi, MD, Dale S. Adler, MD

Abstract

Background: Chronic kidney disease (CKD) is one of the known risk factors for coronary heart disease (CHD). Though electrocardiograms (ECGs) have limited accuracy in determining the true prevalence of CHD, we wondered whether CKD and diabetes mellitus (DM) controlled for hypertension (HTN), had similar prevalences of ECG abnormalities that could reflect underlying coronary heart disease.


Method: Data were collected for 5,942 men and women aged 30 to 69 years in the Tehran Lipid and Glucose Study (TLGS), a cross-sectional phase of a large epidemiologic study first initiated in 1999. ECG findings of all subjects were coded according to Minnesota ECG coding criteria. The Whitehall criteria for abnormal ECG findings that could represent ischemia were utilized. Creatinine clearance (Crcl) was estimated using the Cockroft-Gault equation and diabetes was defined according to the American Diabetic Association (ADA) criteria. Subjects with moderate CKD and without DM were compared with the patients with DM without CKD. HTN prevalence was similar. The analysis was performed for all Whitehall ECG ischemia abnormalities combined, and separately for pathologic Q waves.


Results: In spite of an overall similar prevalence of smoking, and a lower incidence of dyslipidemia and HTN, moderate CKD patients had a higher prevalence of Whitehall criteria abnormal ECG findings compared with the patients with DM. Over 19% of patients with CKD had abnormal ECG findings while 14.7% of diabetic patients had abnormal ECGs (P = 0.02). The prevalence of Q waves was 11.5% in patients with CKD and 10.8% in patients with DM. In an age-matched subgroup of patients with DM and no CKD, the prevalence of ECG abnormalities was 19.3%, similar to the patients with moderate CKD and no DM (19.7%) (P = 0.9). The prevalence of pathologic Q waves in an age-matched group was 11.45%, compared with 11.5%, respectively.


Conclusion: Moderate CKD is a major risk factor for the development of the Whitehall ECG criteria which have been associated with ischemic heart disease. The importance of CKD as a risk factor for ECG abnormalities is comparable with DM. Patients with moderate CKD probably are candidates for aggressive CHD risk modification.


Key Points


* Chronic kidney disease is a condition defined by low creatinine clearance.


* Diabetes mellitus is defined by high blood sugar and is a major risk factor for cardiovascular disease.


* Chronic kidney disease is comparable to diabetes as a cardiovascular risk factor.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853–906.
 
2. Murphy SW. Management of heart failure and coronary artery disease in patients with chronic kidney disease. Semin Dial 2003;16:165–172.
 
3. U.S. Renal Data System: USRDS 1998 Annual Data report: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, August 1998.
 
4. Churchill DN, Taylor DW, Cook RJ, et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992;19:214–234.
 
5. de Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996;7:2044–2054.
 
6. Murphy SW, Foley RN, Parfrey PS. Screening and treatment for cardiovascular disease in patients with chronic renal disease. Am J Kidney Dis 1998;32 (Suppl 3):S184–S199.
 
7. Shlipak MG, Fried LF, Crump C, et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 2002;62:997–1004.
 
8. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121–1129.
 
9. Pinkau T, Hilgers KF, Veelken R, et al. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004;15:517–523.
 
10. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214–2219.
 
11. Levey AS, Coresh J, Balk E, National Kidney Foundation, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–147.
 
12. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (Suppl 1): S17–31.
 
13. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination survey.Am J Kidney Dis 2003;41:1–12.
 
14. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234.
 
15. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.
 
16. Tehran Lipid and Glucose Study. Available at: http://www.erc.ac.ir/tlgs/publications/tlgs1/tlgs1.pdf. Accessed December 9, 2006.
 
17. Azizi F, Ghanbarian A, Madjid M, et al. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999–2000. J Hum Hypertens 2002;16:305–312.
 
18. Azizi F, Rashidi A, Ghanbarian A, et al. Is systolic blood pressure sufficient for classification of blood pressure and determination of hypertension based on JNC-VI in an Iranian adult population? Tehran lipid and glucose study (TLGS). J Hum Hypertens 2003;17:287–291.
 
19. Christiansen DH, Husking JD, Dannenberyn AL, et al. Computer-assisted data collection in multicenter epidemiologic research: the Atherosclerosis Risk in Communities Study. Control Clin Trials 1990;11:101–115.
 
20. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurements and Classification. Boston, MA, John Wright PCG Inc., 1982.
 
21. Quality assurance and quality control. In: Atherosclerosis Risk in Communities Operations Manual. Chapel Hill, NC, ARIC Coordinating Center, 1997.
 
22. Hemingway H, Shipley M, MacFarlane P, et al. Impact of socioeconomic status on coronary mortality in people with symptoms, electrocardiographic abnormalities, both or neither: the original Whitehall study 25-year follow-up. J Epidemiol Community Health 2000;54:510–516.
 
23. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197.
 
24. Chobanian AV, Bakris GL, Black HR, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
 
25. Friedwald WT, Levy RI, Fredrikson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
 
26. World Health Organization. Guideline for Controlling and Monitoring the Tobacco Epidemic.Geneva, 1998a.
 
27. Azizi F, Ghanbarian A, Madjid M, et al. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999–2000. J Hum Hypertens 2002;16:305–312.
 
28. Azizi F, Rahmani M, Ghanbarian A, et al. Serum lipid levels in an Iranian adult population: Tehran Lipid and Glucose Study. Eur J Epidemiol 2003;18:311–319.
 
29. McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679–684.
 
30. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955–962.
 
31. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001;37:1191–1200.
 
32. Hemmelgarn BR, Ghali WA, Quan H, et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 2001;37:64–72.
 
33. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557–1563.
 
34. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169.
 
35. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629–636.
 
36. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 2002;105:2253–2258.
 
37. Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001;38:1398–1407.
 
38. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
 
39. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745–753.
 
40. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218–225.
 
41. Drey N, Roderick P, Mullee M, et al. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003;42:677–684.
 
42. Shlipak MG, Simon JA, Grady D, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001;38:705–711.
 
43. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997;28:557–563.
 
44. Garg AX, Clark WF, Haynes RB, et al. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002;61:1486–1494.
 
45. Duncan L, Heathcote J, Djurdjev O, et al. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant 2001;16:1042–1046.
 
46. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 2004;44:1343–1353.
 
47. O'Neal D, Lee P, Murphy B, et al. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996;27:84–91.